Molecular Partners (Switzerland) Market Value
| MOLN Stock | CHF 4.85 0.03 0.62% |
| Symbol | Molecular |
Molecular Partners 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Molecular Partners' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Molecular Partners.
| 12/04/2022 |
| 11/23/2024 |
If you would invest 0.00 in Molecular Partners on December 4, 2022 and sell it all today you would earn a total of 0.00 from holding Molecular Partners AG or generate 0.0% return on investment in Molecular Partners over 720 days. Molecular Partners is related to or competes with Idorsia, Basilea Pharmaceutica, Santhera Pharmaceuticals, Evolva Holding, and Relief Therapeutics. Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and... More
Molecular Partners Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Molecular Partners' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Molecular Partners AG upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.14 | |||
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 40.85 | |||
| Value At Risk | (6.48) | |||
| Potential Upside | 9.09 |
Molecular Partners Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Molecular Partners' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Molecular Partners' standard deviation. In reality, there are many statistical measures that can use Molecular Partners historical prices to predict the future Molecular Partners' volatility.| Risk Adjusted Performance | 0.013 | |||
| Jensen Alpha | (0.21) | |||
| Total Risk Alpha | (0.88) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0117 |
Molecular Partners Backtested Returns
Molecular Partners has Sharpe Ratio of -0.0064, which conveys that the firm had a -0.0064% return per unit of risk over the last 3 months. Molecular Partners exposes thirty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Molecular Partners' Risk Adjusted Performance of 0.013, mean deviation of 3.75, and Downside Deviation of 4.14 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 1.95, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Molecular Partners will likely underperform. At this point, Molecular Partners has a negative expected return of -0.0365%. Please make sure to verify Molecular Partners' total risk alpha, treynor ratio, and the relationship between the jensen alpha and sortino ratio , to decide if Molecular Partners performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.27 |
Weak reverse predictability
Molecular Partners AG has weak reverse predictability. Overlapping area represents the amount of predictability between Molecular Partners time series from 4th of December 2022 to 29th of November 2023 and 29th of November 2023 to 23rd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Molecular Partners price movement. The serial correlation of -0.27 indicates that nearly 27.0% of current Molecular Partners price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.27 | |
| Spearman Rank Test | -0.47 | |
| Residual Average | 0.0 | |
| Price Variance | 1.13 |
Molecular Partners lagged returns against current returns
Autocorrelation, which is Molecular Partners stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Molecular Partners' stock expected returns. We can calculate the autocorrelation of Molecular Partners returns to help us make a trade decision. For example, suppose you find that Molecular Partners has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Molecular Partners regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Molecular Partners stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Molecular Partners stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Molecular Partners stock over time.
Current vs Lagged Prices |
| Timeline |
Molecular Partners Lagged Returns
When evaluating Molecular Partners' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Molecular Partners stock have on its future price. Molecular Partners autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Molecular Partners autocorrelation shows the relationship between Molecular Partners stock current value and its past values and can show if there is a momentum factor associated with investing in Molecular Partners AG.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Molecular Stock Analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.